Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Size: px
Start display at page:

Download "Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: MAL30013 Title: An Open-Label Comparative Study to Determine the Safety and Efficacy of MALARONE (Atovaquone and Hydrochloride) Versus in the Treatment of Acute Plasmodium falciparum Malaria in Children Weighing 5 and <11kg in Gabon Rationale: Malarial infection is one of the most significant causes of morbidity and mortality in the tropical and sub-tropical parts of the world. Malaria is caused by infection with one or more of the four species of the genus Plasmodium (P. vivax, P. ovale, P. malariae, and P. falciparum). P. falciparum is the predominant and most virulent of the malaria parasites. It is estimated that between 270 and 480 million cases of malaria occur each year in subsaharan Africa. Approximately half of these infections occur in children less than 5 years of age. In areas with the highest transmission rates, malaria mortality is focused in children and pregnant women. Atovaquone and proguanil hydrochloride (atovaquone/proguanil) acts synergistically against chloroquine sensitive and resistant strains of P. falciparum in vitro, and clinical studies have demonstrated enhanced efficacy of the combination compared to either drug alone. Previous pediatric atovaquone/proguanil studies were conducted in children weighing more than 11 kg; however, the greatest morbidity and mortality associated with malarial infection occurs in young children and infants. This study was completed to obtain additional information regarding the safety, efficacy, and population pharmacokinetics of atovaquone/proguanil in children weighing 5kg to <11kg. The study site is situated in a rain forest area on the river Ogooue in Gabon. The predominant infecting species is P. falciparum, responsible for more than 90% of all infections, together with some P. malariae and P. ovale infections. P. falciparum transmission is intense and perennial with an average entomological inoculation rate of around 50 infectious bites per person per year., a 4-aminoquinoline, was chosen as the comparator drug because it is commonly used in many African countries, including Gabon, for treating uncomplicated P. falciparum infections in Gabon. The atovaquone/proguanil dosage used for this study was based on the regimens used in previous pediatric studies; children weighing kg were treated with mg/kg of atovaquone and mg/kg of proguanil hydrochloride. dosing was based on the current standard dosing of 30 mg/kg for children in this weight group. Phase: III Study Period: 20 January December 2000 Study Design: This was a single-center, randomized, open-label, parallel-group study. Subjects were screened for eligibility, randomized (1:1) to be treated for 3 consecutive days with either atovaquone/proguanil or amodiaquine, followed by a 26 day follow-up period. Centers: The study was conducted in 1 center in Gabon. Indication: Treatment of malaria Treatment: Subjects received atovaquone/proguanil or amodiaquine chlorohydrate administered once daily by mouth for three days. Each fixed-dose pediatric strength atovaquone/proguanil tablet contained 62.5 mg atovaquone and 25 mg proguanil hydrochloride. Subjects with body weight 5 kg to <9 kg received 2 tablets/dose, while those with weight 9 kg to <11 kg received 3 tablets/dose. chlorohydrate was a 1% suspension. Objective: The primary objective of this study was to compare the efficacy of atovaquone/proguanil versus amodiaquine in the treatment of children weighing 5kg and <11kg with acute, uncomplicated P. falciparum malaria. Primary Outcome/Efficacy Variable: The primary efficacy measures were 28-day cure rate; the number or subjects with adequate clinical response [ACR], early treatment failure [ETF], and late treatment failure [LTF]);the number of subjects with and without parasitemia at the Day 1, 2, 3, 4, 8, and 29 assessments; molecular evaluation of parasite specimens by polymerase chain reaction (PCR) and single-strand conformational polymorphism (SSCP) analysis for subjects failing treatment; and determination of the WHO Response to Therapy classification. The WHO Response to Therapy classifications were the following: Sensitive (clearance of asexual parasitemia within 7 days of initiation of treatment, without subsequent recrudescence during the 28-day follow-up period) Resistant RI (clearance of asexual parasitemia as in sensitive cases, followed by recrudescence within 28 days) Resistant RII (marked reduction of asexual parasitemia, but no clearance during 7 days) Resistant RIII (no marked reduction of asexual parasitemia during the first 48 hours) Early Treatment Failure (ETF) was defined as development of danger signs or severe malaria on Day 2, 3 or 4 in the presence of parasitemia, a parasitemia count on Day 3>Day 1 or a parasitemia count on Day 4>25% of Day 1. Late Treatment Failure (LTF) was defined as development of danger signs or severe malaria after Day 4 in the 1

2 presence of parasitemia (same species and strain as on Day 1) or parasitemia on or between Day 8 and at last study visit (Day 29) (same species and strain as on Day 1) A subject was determined to have an Adequate Clinical Response (ACR) when they did not develop any of the criteria of ETF or LTF and parasitological clearance was confirmed throughout the Follow-up Period (Day 29). Secondary Outcome/Efficacy Variable(s): The secondary efficacy measures included determination of parasite clearance time (PCT) and fever clearance time (FCT). Statistical Methods: The target sample size was 200 enrolled patients to achieve approximately 180 evaluable subjects. Assuming a follow-up rate of 90% and assuming success rates (28-day cure rates) of 95% and 80% in the atovaquone/proguanil and amodiaquine groups, respectively, 100 subjects per group would give at least 80% power of detecting a difference of 15% between the groups at a 5% significance level. Subjects whose efficacy response was evaluable were included in the per-protocol (PP) population. Subjects who deviated from the protocol were excluded from the PP population. All subjects who were randomized and received at least one dose of treatment were included in the intent-to-treat (ITT) and Safety population. A summary of the numbers for each response (adequate clinical response [ACR], early treatment failure [ETF], and late treatment failure [LTF]), as well as a summary of the 28-day cure rate, was presented for both the per-protocol (PP) and intent-to-treat (ITT) populations. The difference in percentage cure rate between the treatment groups, with 95% confidence interval, was presented, and the success proportions in each treatment group were compared using Fisher s Exact Test. The following assessments were also presented: the number of subjects with and without parasitemia at each study visit, a listing and summary by treatment group by WHO criteria for classification of noncurative and responses resistant to therapy, and a listing of molecular analyses results. PCT and FCT were listed by treatment group and summarized for the PP and ITT populations. PCT and FCT were also displayed for the ITT population using Kaplan-Meier techniques. All adverse events and all drug-related AEs were listed and summarized by body system, frequency, and intensity and by action taken. All laboratory parameters and their changes from Day 1 were summarized by treatment group and visit. Study Population: The diagnosis and main criteria for inclusion were the following: Male or non-childbearing female pediatric subjects weighing 5 kg and <11 kg Documented, uncomplicated P. falciparum infection with acute manifestations (e.g., fever) Parasitemia between 1,000 and 200,000 asexual P. falciparum parasites/µl; subjects with P. malariae or P. ovale co-infection may have been included Parent or guardian willing and able to give written or verbal informed consent and comply with the study protocol Number of Subjects: Planned, N Randomized, N Per-Protocol (PP) Population, N Completed, n (%) 88 (88) 43 (43) Total Number Subjects Withdrawn, N (%) 12 (12) 57 (57) Withdrawn Due to Adverse Events, n (%) 3 (3) 3 (3) Withdrawn for Other Reasons, including Lack of Efficacy, n (%) 9 (9) 54 (54) Demographics: Females:Males 45:55 45:55 Mean Age, Months (SD) 17.2 (8.2) 17.9 (9.2) Black, n (%) 100 (100) 100 (100) Weight 5 kg to <9 kg, n (%) 28 (28) 29 (29) Weight 9 kg to <11 kg, n (%) 72 (72) 71 (71) Mean Weight, kg (SD) 9.41 (1.35) 9.51 (1.32) Primary Efficacy Results: 28-Day Cure Rate Success, n (%) 87 (87) 42 (42) Difference Between Treatments 45% 2

3 95% Confidence Interval for Difference 33, 57 p-value for Difference <0.001 Summary of Efficacy Response Adequate Clinical Response (%) 87 (87%) 42 (42%) Early Treatment Failure (%) 2 (2%) 3 (3%) Fail-withdrew due to treatment related AE (%) 1 (1%) 0 Late Treatment Failure (%) 3 (3%) 34 (34%) Unevaluable (%) 7 (7%) 21 (21%) Parasitological Outcome With Parasitemia on Day 1, n (%) 100 (100) 100 (100) With Parasitemia on Day 2, n (%) 96 (96) 97 (97) With Parasitemia on Day 3, n (%) 74 (74) 60 (60) With Parasitemia on Day 4, n (%) 22 (22) 21 (21) With Parasitemia on Day 8, n (%) 0 2 (2) With Parasitemia on Day 29, n (%) 3 (3) 31 (31) Without Parasitemia on Day 1, n (%) 0 0 Without Parasitemia on Day 2, n (%) 1 (1) 1 (1) Without Parasitemia on Day 3, n (%) 18 (18) 35 (35) Without Parasitemia on Day 4, n (%) 69 (69) 68 (68) Without Parasitemia on Day 8, n (%) 91 (90) 81 (81) Without Parasitemia on Day 29, n (%) 88 (88) 43 (43) Unevaluable for Parasitemia on Day 1, n (%) 0 0 Unevaluable for Parasitemia on Day 2, n (%) 3 (3) 2 (2) Unevaluable for Parasitemia on Day 3, n (%) 8 (8) 5 (5) Unevaluable for Parasitemia on Day 4, n (%) 9 (9) 11 (11) Unevaluable for Parasitemia on Day 8, n (%) 9 (9) 17 (17) Unevaluable for Parasitemia on Day 29, n (%) 9 (9) 26 (26) Molecular Analysis of Treatment Failure N 4 29 Failures due to re-infection (based on Genetic Fingerprinting) n (%) 2 (50) 15 (52) WHO Response Classification Sensitive, n (%) 87 (87) 42 (42) Resistant RI, n (%) 3 (3) 31 (31) Resistant RII, n (%) 0 2 (2) Resistant RIII, n (%) 2 (2) 4 (4) Unevaluable, n (%) 8 (8) 21 (21) Secondary Efficacy Results: Parasite Clearance Time, h N Mean (SD) 86.2 (45.0) 74.4 (43.9) Median Range Fever Clearance Time, h N Mean (SD) 54.8 (48.4) 39.7 (32.8) Median

4 Range Safety Results: On-therapy adverse events (AEs) were defined as all AEs where the onset date was on or after the first day of treatment and before or on the last day of the 26-day follow-up period. On-therapy serious adverse events (SAEs) include all serious AEs that occurred on treatment or with onset within 26 days of the end of treatment. Most Frequent Adverse Events On-Therapy N (Safety) n (%) n (%) Subjects with any AE(s) 48 (48) 43 (43) Cough 14 (14) 13 (13) Diarrhea 12 (12) 15 (15) Vomiting 7 (7) 7 (7) Respiratory Tract Infection 4 (4) 0 Sore Throat 3 (3) 0 Worms in Stool 3 (3) 0 Upper Respiratory Tract Infection 2 (2) 2 (2) Decreased Appetite 2 (2) 1 (1) Fever 2 (2) 1 (1) Constipation 2 (2) 0 Helminthiasis 2 (2) 0 Common Cold 1 (1) 4 (4) Weakness 1 (1) 4 (4) Lower Respiratory Tract Infection 1 (1) 2 (2) Fatigue 1 (1) 1 (1) Pruritus 1 (1) 1 (1) Recurrent Diarrhea 1 (1) 1 (1) Rhinitis 1 (1) 1 (1) Intestinal Helminthiasis 0 3 (3) Abdominal Pain 0 1 (1) Anemia 0 1 (1) Dehydration 0 1 (1) Dystonic Movement(s) 0 1 (1) Nausea 0 1 (1) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] N (Safety) Subjects with Non-Fatal SAEs, n (%) 1 (1) 3 (3) n (%) [related] n (%) [related] Convulsions 1 (1) [0] 0 Anemia 0 1 (1) [0] Lower Respiratory Tract Infection 0 1 (1) [0] Dystonic Movement(s) 0 1 (1) [0] Subjects with Fatal SAEs 0 0 4

5 Conclusion: See publication below. Publications: Borrmann S. Faucher JF. Bagaphou T. Missinou MA. Binder RK. Pabisch S. Rezbach P. Matsiegui PB. Lell B. Miller G. Kremsner PG. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clinical Infectious Diseases. 37(11):1441-7, 2003 Abstract: Atovaquone and proguanil versus amodiaquine in the treatment of uncomplicated plasmodium falciparum malaria in children weighing >+5 and <11 kg in gabon. Borrmann, S, Faucher, J F, Binder, R K, Miller, G B, Lell, B, and Kremsner, P G American Society of Tropical Medicine and Hygiene 50th Annual Meeting 11/11/2001 Atlanta, GA; USA Abstract: Atovaquone and proguanil versus amodiaquine in the treatment of uncomplicated plasmodium falciparum malaria in children weighing 5 and < 11kg in gabon. Faucher, J F, Binder, R K, Lell, B, Kremsner, P G, Borrmann, S, and Miller, G B 3rd European Congress on Tropical Medicine and International Health 9/8/2002 Lisbon; Portugal Date Updated: 23-May

Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children

Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children MAJOR ARTICLE Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children Steffen Borrmann, 1,2 Jean-François Faucher, 1 Thierry

More information

Sponsor / Company: Sanofi Drug substance(s): SSR103371

Sponsor / Company: Sanofi Drug substance(s): SSR103371 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Sponsor / Company: Sanofi Drug substance(s): artesunate plus amodiaquine Title of the study:

Sponsor / Company: Sanofi Drug substance(s): artesunate plus amodiaquine Title of the study: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Statistical Analysis Plan (SAP)

Statistical Analysis Plan (SAP) Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents

More information

A Simple Dose Regimen of Artesunate and Amodiaquine Based on Arm Span- or Age Range for Childhood Falciparum Malaria: A Preliminary Evaluation

A Simple Dose Regimen of Artesunate and Amodiaquine Based on Arm Span- or Age Range for Childhood Falciparum Malaria: A Preliminary Evaluation JOURNAL OF TROPICAL PEDIATRICS, VOL. 58, NO. 4, 2012 A Simple Dose Regimen of Artesunate and Amodiaquine Based on Arm Span- or Age Range for Childhood Falciparum Malaria: A Preliminary Evaluation by Akintunde

More information

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Anti-Malaria Chemotherapy

Anti-Malaria Chemotherapy Anti-Malaria Chemotherapy Causal Prophylaxis prevent infection (ie, liver stage) Suppressive Prophylaxis prevent clinical disease (ie, blood stages) Treatment Therapy (or clinical cure) relieve symptoms

More information

Clinical Analysis Report For Study Sample Study

Clinical Analysis Report For Study Sample Study Clinical Analysis Report For Study Sample Study Automated report generated by WWARN May 9, 2014 Falciparum class org.wwarn.csr.clinicalstudyreport Version 1.020140508-1558 1 Contents 1 Executive Summary

More information

Symptoms of Malaria. Young children, pregnant women, immunosuppressed and elderly travellers are particularly at risk of severe malaria.

Symptoms of Malaria. Young children, pregnant women, immunosuppressed and elderly travellers are particularly at risk of severe malaria. Preventing Malaria 1 Malaria is the world s most prevalent parasitic disease, accounting for an estimated 216 million cases with 655,000 deaths annually. Many people acquire malaria during travel to tropical

More information

Scenario#1 Fever from Kenya. New Drugs for Malaria

Scenario#1 Fever from Kenya. New Drugs for Malaria New Drugs for Malaria This talk may be politically incorrect or in bad 1 taste.viewer discretion is advised 2 Scenario#1 Fever from Kenya A 37 year old traveller returns from a one month vacation in rural

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)

PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

ATOVAQUONE PROGUANIL INFORMATION FOR THE PATIENT

ATOVAQUONE PROGUANIL INFORMATION FOR THE PATIENT ATOVAQUONE PROGUANIL INFORMATION FOR THE PATIENT Please read this information carefully before taking your medication. If you have any questions ask your doctor or pharmacist. What is malaria? Malaria

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

14th Stakeholders Meeting

14th Stakeholders Meeting 14th Stakeholders Meeting Steady progress towards malaria elimination: Interventions for today and tomorrow Denpasar, Bali 11 12 October 2017 David Hughes, Novartis 12th October 2017 Defeating Malaria

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Anas Raed. - Zaid Emad. - Malik Zuhlof

Anas Raed. - Zaid Emad. - Malik Zuhlof - 6 - Anas Raed - Zaid Emad - Malik Zuhlof 1 P a g e - This lecture started with the excellent presentation of chronic fatigue syndrome and the role of Vitamin B12 in its treatment by our colleague Osama

More information

Malaria. Edwin J. Asturias, MD

Malaria. Edwin J. Asturias, MD Malaria Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public Health Global Health and Disasters Course

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment

Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment Tropical Medicine and International Health doi:10.1111/j.1365-3156.2007.01977.x volume 13 no 1 pp 83 90 january 2008 Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment

More information

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics> The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Northern Ethiopia

Clinical Study Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Northern Ethiopia Malaria Research and Treatment Volume 2012, Article ID 548710, 6 pages doi:10.1155/2012/548710 Clinical Study Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Malaria. Population at Risk. Infectious Disease epidemiology BMTRY 713 (Lecture 23) Epidemiology of Malaria. April 6, Selassie AW (DPHS) 1

Malaria. Population at Risk. Infectious Disease epidemiology BMTRY 713 (Lecture 23) Epidemiology of Malaria. April 6, Selassie AW (DPHS) 1 Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 23 Vector-Borne Disease (Part II) Epidemiology of Malaria Learning Objectives 1. Overview of malaria Global perspectives 2. Identify

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Malaria. is a mosquito-born disease causing about 3 million deaths a year world-wide. Many are children under the age of 5.

Malaria. is a mosquito-born disease causing about 3 million deaths a year world-wide. Many are children under the age of 5. Malaria is a mosquito-born disease causing about 3 million deaths a year world-wide. Many are children under the age of 5. The parasite is transmitted by bites from the female anopheles mosquito. Currently,

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Atovaquone-proguanil for treating uncomplicated malaria (Review)

Atovaquone-proguanil for treating uncomplicated malaria (Review) (Review) Osei-Akoto A, Orton LC, Owusu-Ofori S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Malaria Updates. Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine

Malaria Updates. Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine Malaria Updates Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine Outline General epidemiology of malaria in the Philippines P falciparum Updates in treatment Recognizing

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

DOUBLE BLIND RANDOMISED CLINICAL TRIAL OF TWO DIFFERENT REGIMENS OF ORAL ARTESUNATE IN FALCIPARUM MALARIA

DOUBLE BLIND RANDOMISED CLINICAL TRIAL OF TWO DIFFERENT REGIMENS OF ORAL ARTESUNATE IN FALCIPARUM MALARIA DOUBLE BLIND RANDOMISED CLINICAL TRIAL OF TWO DIFFERENT REGIMENS OF ORAL ARTESUNATE IN FALCIPARUM MALARIA Danai Bunnag, Chaisin Viravan, Sornchai Looareesuwan, Juntra Karbwang and T-ranakchit Harinasuta

More information

Invest in the future, defeat malaria

Invest in the future, defeat malaria Invest in the future, defeat malaria Malaria is caused by parasites from the genus Plasmodium, which are spread to people by infected mosquitoes. There are five species of Plasmodium that can infect humans.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HALOFANTRINE HYDROCHLORIDE - EFFICACY AND SAFETY IN CHILDREN WITH ACUTE MALARIA

HALOFANTRINE HYDROCHLORIDE - EFFICACY AND SAFETY IN CHILDREN WITH ACUTE MALARIA HALOFANTRINE HYDROCHLORIDE - EFFICACY AND SAFETY IN CHILDREN WITH ACUTE MALARIA Pages with reference to book, From 8 To 10 Mushtaq A. Khan, Gui Nayyer Rehman, S.A. Qazi ( Children Hospital, Pakistan Institute

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Increase in temperatures in Africa, rise in humidity creating new water sources and the start of agriculture in the Middle East and North East Africa

Increase in temperatures in Africa, rise in humidity creating new water sources and the start of agriculture in the Middle East and North East Africa 1 HISTORY 2 Malaria has been known to mankind for thousands of years. Increase in temperatures in Africa, rise in humidity creating new water sources and the start of agriculture in the Middle East and

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Malaria. Traveler Summary. Key Points. Introduction. Risk Areas

Malaria. Traveler Summary. Key Points. Introduction. Risk Areas Malaria Traveler Summary Key Points Malaria is an infection caused by a parasite that lives within the red blood cells and is acquired through the bite of mosquitoes which generally feed at night. This

More information

MONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND

MONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH MONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND C Rojanawatsirivej 1, S Vijaykadga 1, I Amklad 1, P Wilairatna

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Elements for a public summary

Elements for a public summary VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Malaria is caused by mosquito bites whereby the malaria parasites can enter the body and then live in body tissues such as red

More information

Directorate of National Vector Borne Disease Control Programme

Directorate of National Vector Borne Disease Control Programme NATIONAL DRUG POLICY ON MALARIA (2008) Directorate of National Vector Borne Disease Control Programme (Directorate General of Health Services) Ministry of Health and Family Welfare 22-Shamnath Marg,, Delhi-110054..

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 06/2013

See 17 for PATIENT COUNSELING INFORMATION. Revised: 06/2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MALARONE safely and effectively. See full prescribing information for MALARONE. MALARONE (atovaquone

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Downloaded from:

Downloaded from: Abreha, T; Alemayehu, B; Assefa, A; Awab, GR; Baird, JK; Bezabih, B; Cheah, PY; Day, NP; Devine, A; Dorda, M; Dondorp, AM; Girma, S; Hien, TT; Jima, D; Kassa, M; Kebende, A; Khu, NH; Leslie, T; Ley, B;

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1

Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative

More information

PARASITOLOGY CASE HISTORY #14 (BLOOD PARASITES) (Lynne S. Garcia)

PARASITOLOGY CASE HISTORY #14 (BLOOD PARASITES) (Lynne S. Garcia) PARASITOLOGY CASE HISTORY #14 (BLOOD PARASITES) (Lynne S. Garcia) A 37-year-old woman, who had traveled to New Guinea for several weeks, presented to the medical clinic with fever, chills, and rigors within

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Secondary Outcome/Efficacy Variable(s):

Secondary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial

A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial The Four Artemisinin-Based Combinations (4ABC) Study Group* "

More information

Malaria parasites Malaria parasites are micro-organisms that belong to the genus Plasmodium. There are more than 100 species of Plasmodium, which can infect many animal species such as reptiles, birds,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Population: 12 years and older A EF Calcipotriene Foam, 0.005%

Study Population: 12 years and older A EF Calcipotriene Foam, 0.005% Study No.: CAL.203 Title: A Randomized, Open-Label Study to Assess the Bioavailability of Emulsion Formulation Foam, 0.005%, and Dovonex, 0.005%, in Patients with Mild to Moderate Plaque-Type Psoriasis

More information

Analysis of safety The analysis was performed on the Total Vaccinated cohort.

Analysis of safety The analysis was performed on the Total Vaccinated cohort. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Kato, N. et al, Nature, 2016, Accelerated Article Preview. Celeste Alverez Current Literature 9/10/ /10/2016 Celeste Wipf Group 1

Kato, N. et al, Nature, 2016, Accelerated Article Preview. Celeste Alverez Current Literature 9/10/ /10/2016 Celeste Wipf Group 1 Kato, N. et al, Nature, 2016, Accelerated Article Preview Celeste Alverez Current Literature 9/10/2016 9/10/2016 Celeste Alverez @ Wipf Group 1 Malaria Caused by Plasmodium parasites Carried by 30-40 species

More information

Downloaded from:

Downloaded from: Myrick, A; Leemann, E; Dokomajilar, C; Hopkins, H; Dorsey, G; Kamya, MR; Rosenthal, PJ (2006) Short report: Dynamics of Plasmodium falciparum malaria after sub-optimal therapy in Uganda. The American journal

More information

ISSN X (Print) Original Research Article. DOI: /sjams India

ISSN X (Print) Original Research Article. DOI: /sjams India DOI: 10.21276/sjams.2016.4.6.22 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(6B):1981-198 5 Scholars Academic and Scientific Publisher (An International Publisher

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Partnerships in action

Partnerships in action From field experience to the discovery of antimalarials: Partnerships in action Chairman: Wilfred Mbacham, Biotechnologies Centre, University of Yaounde I, Cameroon Co-chairmen: Timothy Wells, Chief Scientific

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Stephan Duparc 1*, Isabelle Borghini-Fuhrer 1, J Carl Craft 1,2, Sarah Arbe-Barnes 3, Robert M Miller 3, Chang-Sik Shin 4 and Lawrence Fleckenstein 5

Stephan Duparc 1*, Isabelle Borghini-Fuhrer 1, J Carl Craft 1,2, Sarah Arbe-Barnes 3, Robert M Miller 3, Chang-Sik Shin 4 and Lawrence Fleckenstein 5 Duparc et al. Malaria Journal 213, 12:7 http://www.malariajournal.com/content/12/1/7 RESEARCH Open Access Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis

More information

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER

More information

Advisory on Malaria. What is Malaria? 21 November Malaria is a serious, lifethreatening

Advisory on Malaria. What is Malaria? 21 November Malaria is a serious, lifethreatening 21 November 2018 Advisory on Malaria What is Malaria? Malaria is a serious, lifethreatening disease causes by Plasmodium parasite which is transmitted to humans from the bite of a female Anopheles mosquito.

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Title: Author: Benji Mathews. Date: 1/4/08. Key words: Malaria, Travel, Medications

Title: Author: Benji Mathews. Date: 1/4/08. Key words: Malaria, Travel, Medications Title: Author: Benji Mathews Date: 1/4/08 Key words: Malaria, Travel, Medications Abstract: Malaria is an insect borne disease widespread in tropical and subtropical regions of the world. It causes about

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY ISBN

METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY ISBN METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY ISBN 978 92 4 159753 1 METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY WHO Library Cataloguing-in-Publication

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information